A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan

Conclusions Seribantumab/cetuximab was well tolerated and patients experienced toxicities typical to EGFR inhibition. Unlike the seribantumab/cetuximab doublet, seribantumab/cetuximab/irinotecan was difficult to tolerate in this heavily pretreated population. There was limited efficacy of the combination therapy.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research